socalTECH

NOVEMBER 7, 2013

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.

Thousand Oaks 164

Thousand Oaks UCLA Venture Capital Equity 164

socalTECH

JULY 2, 2010

Thousand Oaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Source of the new funding was not disclosed. The filing indicates the round came from five investors.

Thousand Oaks 150

Thousand Oaks Equity Funding Capital 150

Xconomy

JULY 22, 2016

. —Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs. Also in Cambridge, Oncorus debuted with a $57 million round and a plan to develop next-gen oncolytic viruses, a type of cancer immunotherapy tool.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

JUNE 10, 2016

Guardant is funding a series of trials around the country in people whose genetic or lifestyle profiles put them at high risk of five types of cancer. —More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67